Terms: = Bone cancer AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269 AND Treatment
4 results:
1. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Ropa J; Saha N; Hu H; Peterson LF; Talpaz M; Muntean AG
Haematologica; 2020 Sep; 105(9):2273-2285. PubMed ID: 33054052
[TBL] [Abstract] [Full Text] [Related]
2. NUP98-PHF23 fusion is recurrent in acute myeloid leukemia and shares gene expression signature of leukemic stem cells.
Ho H; Skaist AM; Pallavajjala A; Yonescu R; Batista D; Wheelan SJ; Ning Y
Leuk Res; 2016 Jun; 45():1-7. PubMed ID: 27060678
[TBL] [Abstract] [Full Text] [Related]
3. Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS; Selemon H; Elton SM; Parinandi NL
Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696
[TBL] [Abstract] [Full Text] [Related]
4. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
[TBL] [Abstract] [Full Text] [Related]
